Literature DB >> 20686044

Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.

Katie J Doores1, Dennis R Burton.   

Abstract

The HIV-1-specific antibodies PG9 and PG16 show marked cross-isolate neutralization breadth and potency. Antibody neutralization has been shown to be dependent on the presence of N-linked glycosylation at position 160 in gp120. We show here that (i) the loss of several key glycosylation sites in the V1, V2, and V3 loops; (ii) the generation of pseudoviruses in the presence of various glycosidase inhibitors; and (iii) the growth of pseudoviruses in a mutant cell line (GnT1(-/-)) that alters envelope glycosylation patterns all have significant effects on the sensitivity of virus to neutralization by PG9 and PG16. However, the interaction of antibody is not inhibited by sugar monosaccharides corresponding to those found in glycans on the HIV surface. We show that some of the glycosylation effects described are isolate dependent and others are universal and can be used as diagnostic for the presence of PG9 and PG16-like antibodies in the sera of HIV-1-infected patients. The results suggest that PG9 and PG16 recognize a conformational epitope that is dependent on glycosylation at specific variable loop N-linked sites. This information may be valuable for the design of immunogens to elicit PG9 and PG16-like antibodies, as well as constructs for cocrystallization studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20686044      PMCID: PMC2950566          DOI: 10.1128/JVI.00552-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells.

Authors:  T B Geijtenbeek; D S Kwon; R Torensma; S J van Vliet; G C van Duijnhoven; J Middel; I L Cornelissen; H S Nottet; V N KewalRamani; D R Littman; C G Figdor; Y van Kooyk
Journal:  Cell       Date:  2000-03-03       Impact factor: 41.582

2.  Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells.

Authors:  X Zhu; C Borchers; R J Bienstock; K B Tomer
Journal:  Biochemistry       Date:  2000-09-19       Impact factor: 3.162

Review 3.  Antibodies, viruses and vaccines.

Authors:  Dennis R Burton
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

4.  Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

Authors:  M B Zwick; M Wang; P Poignard; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism.

Authors:  R A Ogert; M K Lee; W Ross; A Buckler-White; M A Martin; M W Cho
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

6.  Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line.

Authors:  Philip J Reeves; Nico Callewaert; Roland Contreras; H Gobind Khorana
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

7.  Immunology and the elusive AIDS vaccine.

Authors:  Herbert W Virgin; Bruce D Walker
Journal:  Nature       Date:  2010-03-11       Impact factor: 49.962

Review 8.  Folding of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum.

Authors:  A Land; I Braakman
Journal:  Biochimie       Date:  2001-08       Impact factor: 4.079

9.  Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response.

Authors:  Miriam I Quiñones-Kochs; Linda Buonocore; John K Rose
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

10.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more
  157 in total

Review 1.  Emerging technologies for making glycan-defined glycoproteins.

Authors:  Lai-Xi Wang; Joseph V Lomino
Journal:  ACS Chem Biol       Date:  2011-12-14       Impact factor: 5.100

2.  A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Ivelin Georgiev; Sijy O'Dell; Gwo-Yu Chuang; Ryan P Staupe; Jason S McLellan; Jason Gorman; Marie Pancera; Mattia Bonsignori; Barton F Haynes; Dennis R Burton; Wayne C Koff; Peter D Kwong; John R Mascola
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

3.  The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter.

Authors:  Rebecca M Lynch; Rong Rong; Saikat Boliar; Anurag Sethi; Bing Li; Joseph Mulenga; Susan Allen; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

4.  HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.

Authors:  Tommy Tong; Ema T Crooks; Keiko Osawa; James M Binley
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

5.  New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency.

Authors:  Nicole A Doria-Rose; Jinal N Bhiman; Ryan S Roark; Chaim A Schramm; Jason Gorman; Gwo-Yu Chuang; Marie Pancera; Evan M Cale; Michael J Ernandes; Mark K Louder; Mangaiarkarasi Asokan; Robert T Bailer; Aliaksandr Druz; Isabella R Fraschilla; Nigel J Garrett; Marissa Jarosinski; Rebecca M Lynch; Krisha McKee; Sijy O'Dell; Amarendra Pegu; Stephen D Schmidt; Ryan P Staupe; Matthew S Sutton; Keyun Wang; Constantinos Kurt Wibmer; Barton F Haynes; Salim Abdool-Karim; Lawrence Shapiro; Peter D Kwong; Penny L Moore; Lynn Morris; John R Mascola
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

6.  A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans.

Authors:  Devin Sok; Matthias Pauthner; Bryan Briney; Jeong Hyun Lee; Karen L Saye-Francisco; Jessica Hsueh; Alejandra Ramos; Khoa M Le; Meaghan Jones; Joseph G Jardine; Raiza Bastidas; Anita Sarkar; Chi-Hui Liang; Sachin S Shivatare; Chung-Yi Wu; William R Schief; Chi-Huey Wong; Ian A Wilson; Andrew B Ward; Jiang Zhu; Pascal Poignard; Dennis R Burton
Journal:  Immunity       Date:  2016-07-19       Impact factor: 31.745

7.  The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

Authors:  Nicos Karasavvas; Erik Billings; Mangala Rao; Constance Williams; Susan Zolla-Pazner; Robert T Bailer; Richard A Koup; Sirinan Madnote; Duangnapa Arworn; Xiaoying Shen; Georgia D Tomaras; Jeffrey R Currier; Mike Jiang; Craig Magaret; Charla Andrews; Raphael Gottardo; Peter Gilbert; Timothy J Cardozo; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Robert Paris; Kelli Greene; Hongmei Gao; Sanjay Gurunathan; Jim Tartaglia; Faruk Sinangil; Bette T Korber; David C Montefiori; John R Mascola; Merlin L Robb; Barton F Haynes; Viseth Ngauy; Nelson L Michael; Jerome H Kim; Mark S de Souza
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-04       Impact factor: 2.205

8.  Antigenic properties of the HIV envelope on virions in solution.

Authors:  Krishanu Ray; Meron Mengistu; Lei Yu; George K Lewis; Joseph R Lakowicz; Anthony L DeVico
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

Review 9.  Chemical and chemoenzymatic synthesis of glycoproteins for deciphering functions.

Authors:  Lai-Xi Wang; Mohammed N Amin
Journal:  Chem Biol       Date:  2014-01-16

10.  2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies.

Authors:  Katie J Doores; Michael Huber; Khoa M Le; Sheng-Kai Wang; Colleen Doyle-Cooper; Anthony Cooper; Ralph Pantophlet; Chi-Huey Wong; David Nemazee; Dennis R Burton
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.